Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring: Prospective Health-economic Evaluation in Patients in Remission With Atypical Hemolytic Uraemic Syndrome Requiring Long-term Treatment
Latest Information Update: 12 Mar 2024
At a glance
- Drugs Eculizumab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Therapeutic Use
- Acronyms EspacECU
- 08 Mar 2024 Status changed from active, no longer recruiting to completed.
- 01 Feb 2024 Planned End Date changed from 1 Feb 2024 to 1 Jun 2024.
- 01 Feb 2024 Status changed from recruiting to active, no longer recruiting.